Peptonic’s Board of Directors resolves on a directed issue of units to guarantors in connection with the completed rights issue

Peptonic Medical's board on 12 Feb 2026 resolved a directed issue of 1,005,578 units to guarantors (each unit = 100 newly issued shares + 100 warrants series TO6) at SEK 0.16 per unit (SEK 0.0016 per share), settled by set-off against guarantee compensation. The issuance results in 100,557,800 new shares and 100,557,800 warrants, increasing shares from 20,624,009,514 to 20,724,567,314 (≈0.5% dilution); full exercise of TO6 would add a further 100,557,800 shares (~0.5% additional dilution). The board cites contractual obligations and a preference to preserve liquidity by issuing units instead of paying cash; the Rights Issue was ~67.1% secured (≈31.5% subscription undertakings and ≈35.6% guarantees).

Analysis

Market structure: The guarantors converting cash compensation into 100.6m shares (0.5% dilution now; +0.5% if TO6 exercised) directly benefits Peptonic’s near-term liquidity and guarantors who avoid cash exposure. Existing free float and retail holders face modest dilution and a possible future supply overhang from TO6; impact on pricing power in the OTC women's-health niche is minimal unless proceeds are wasted. The rights issue subscription pattern (31.5% undertakings, 35.6% guarantees) signals weak voluntary investor demand and higher cost of capital going forward.

Risk assessment: Immediate effect (days) is improved liquidity and likely muted share-price reaction; short-term (weeks–months) risks center on sentiment if guarantors sell or warrants trade; long-term (12–24 months) hinge on execution of US/European expansion using the preserved cash. Tail risks: coordinated disposal by guarantors, adverse FDA/FTC action in US channels, or failure to translate runway into revenue growth — any would compress valuation >30–50%. Hidden dependency: success depends on burn reduction milestones and the exercise terms/timing of TO6, currently an asymmetric overhang.

Trade implications: For active accounts, a small tactical long in Peptonic (1–2% portfolio weight) is justified if using downside protection: buy 6–9 month puts struck ~20% below entry for 30–50% notional to limit downside. Consider buying TO6 warrants only if market prices them >20% below implied value after revealing strike/tenor — target 50–100% return if product/expansion news arrives within 12 months. Reallocate 2–4% from small-cap Nordic healthcare into defensive OTC giants (JNJ, HLN) to reduce financing-risk exposure.

Contrarian angle: The market may overestimate dilution — 0.5–1.0% is immaterial vs execution risk; the real value swing comes from runway extension enabling commercialization or M&A. If Peptonic converts cash savings into 30–50% faster US rollout within 12 months, upside could be >2x from deeply discounted small-cap levels; conversely, if warrants flood the market and revenues stall, downside could exceed 40%. Observe guarantor trading patterns and TO6 pricing as the decisive short-term signals.

Key Decisions for Investors

• Establish a tactical 1–2% long position in Peptonic Medical AB within 2 weeks; hedge with 6–9 month put options struck ~20% below purchase for 30–50% notional exposure. Target exit: +40% gain or stop-loss at -20% (adjust if fundamental news changes runway/timing).
• Only buy TO6 warrants if quoted price implies >20% discount to theoretical value after strike/expiry are public; position size 0.5–1% portfolio, hold 6–12 months and take profit at +50–100% or if warrants approach intrinsic parity.
• If unable to hedge with liquid options, avoid >1% outright exposure to Peptonic and instead reduce small-cap Nordic healthcare exposure by 2–4% and reallocate to defensive OTC stocks JNJ and HLN over the next 30 days to lower financing/dilution risk.
• Monitor three triggers over next 60 days and act: (A) guarantor block sales >0.5% of float in a single week — exit long positions; (B) disclosure of TO6 strike/expiry that implies >5% potential dilution within 12 months — trim positions by 50%; (C) announcement of US/European commercialization milestones or acquisition within 12 months — add to positions up to a total 3–4% weight.